FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220795434> ?p ?o ?g. }

• W4220795434 endingPage "1347" @default.
• W4220795434 startingPage "1340" @default.
• W4220795434 abstract "Absorb bioresorbable vascular scaffold (BVS)-related events have been reported between 1 and 3 years - the period of active scaffold bioresorption. Data on the performance of the Absorb BVS in daily clinical practice beyond this time point are scarce.This report aimed to provide the final five-year clinical follow-up of the Absorb BVS in comparison with the XIENCE everolimus-eluting stent (EES). In addition, we evaluated the effect of prolonged dual antiplatelet therapy (DAPT) administration on events in the scaffold group.AIDA was a multicentre, investigator-initiated, non-inferiority trial, in which 1,845 unselected patients with coronary artery disease were randomly assigned to either the Absorb BVS (n=924) or the XIENCE EES (n=921). Target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction or target vessel revascularisation, was the primary endpoint. Scaffold thrombosis cases were matched with controls and tested for the effect of prolonged DAPT.Up to five-year follow-up, there was no difference in TVF between the Absorb BVS (17.7%) and the XIENCE EES (16.1%) (hazard ratio [HR] 1.31, 95% confidence interval [CI]: 0.90-1.41; p=0.302). Definite or probable device thrombosis (DT) occurred in 43 patients (4.8%) in the scaffold group compared to 13 patients (1.5%) in the stent group (HR 3.32, 95% CI: 1.78-6.17; p<0.001). DT between 3 and 4 years occurred six times in the Absorb arm versus three times in the XIENCE arm. Between 4 and 5 years, the incidence was three versus two, respectively. Of those three DT in the scaffold group, two occurred in XIENCE EES-treated lesions. The odds ratio of scaffold thrombosis in patients on DAPT compared to off DAPT throughout five-year follow-up was 0.36 (95% CI: 0.15-0.86).The excess risk of the Absorb BVS on late adverse events, in particular device thrombosis, in routine PCI continues up to 4 years and seems to plateau afterwards. Clinical Trial Registration ClinicalTrials.gov: NCT01858077." @default.
• W4220795434 created "2022-04-03" @default.
• W4220795434 creator A5003578699 @default.
• W4220795434 creator A5006701743 @default.
• W4220795434 creator A5012791093 @default.
• W4220795434 creator A5038079536 @default.
• W4220795434 creator A5041156414 @default.
• W4220795434 creator A5043444924 @default.
• W4220795434 creator A5045447616 @default.
• W4220795434 creator A5048845661 @default.
• W4220795434 creator A5054452062 @default.
• W4220795434 creator A5055195060 @default.
• W4220795434 creator A5065566368 @default.
• W4220795434 creator A5077532206 @default.
• W4220795434 creator A5090267798 @default.
• W4220795434 creator A5091465562 @default.
• W4220795434 date "2022-03-01" @default.
• W4220795434 modified "2023-10-15" @default.
• W4220795434 title "Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial" @default.
• W4220795434 cites W2060063218 @default.
• W4220795434 cites W2087150869 @default.
• W4220795434 cites W2099871228 @default.
• W4220795434 cites W2125173296 @default.
• W4220795434 cites W2147071306 @default.
• W4220795434 cites W2180527161 @default.
• W4220795434 cites W2409398270 @default.
• W4220795434 cites W2543693155 @default.
• W4220795434 cites W2598919558 @default.
• W4220795434 cites W2610410689 @default.
• W4220795434 cites W2765394986 @default.
• W4220795434 cites W2765992454 @default.
• W4220795434 cites W2766648702 @default.
• W4220795434 cites W2766931456 @default.
• W4220795434 cites W2804104763 @default.
• W4220795434 cites W2883793745 @default.
• W4220795434 cites W2904877181 @default.
• W4220795434 cites W2975517918 @default.
• W4220795434 cites W2976391846 @default.
• W4220795434 cites W2991458959 @default.
• W4220795434 cites W2997041883 @default.
• W4220795434 cites W3033506954 @default.
• W4220795434 cites W3039098849 @default.
• W4220795434 cites W3123833391 @default.
• W4220795434 cites W4211104669 @default.
• W4220795434 cites W4292856638 @default.
• W4220795434 cites W85010934 @default.
• W4220795434 doi "https://doi.org/10.4244/eij-d-21-00419" @default.
• W4220795434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34483094" @default.
• W4220795434 hasPublicationYear "2022" @default.
• W4220795434 type Work @default.
• W4220795434 citedByCount "11" @default.
• W4220795434 countsByYear W42207954342022 @default.
• W4220795434 countsByYear W42207954342023 @default.
• W4220795434 crossrefType "journal-article" @default.
• W4220795434 hasAuthorship W4220795434A5003578699 @default.
• W4220795434 hasAuthorship W4220795434A5006701743 @default.
• W4220795434 hasAuthorship W4220795434A5012791093 @default.
• W4220795434 hasAuthorship W4220795434A5038079536 @default.
• W4220795434 hasAuthorship W4220795434A5041156414 @default.
• W4220795434 hasAuthorship W4220795434A5043444924 @default.
• W4220795434 hasAuthorship W4220795434A5045447616 @default.
• W4220795434 hasAuthorship W4220795434A5048845661 @default.
• W4220795434 hasAuthorship W4220795434A5054452062 @default.
• W4220795434 hasAuthorship W4220795434A5055195060 @default.
• W4220795434 hasAuthorship W4220795434A5065566368 @default.
• W4220795434 hasAuthorship W4220795434A5077532206 @default.
• W4220795434 hasAuthorship W4220795434A5090267798 @default.
• W4220795434 hasAuthorship W4220795434A5091465562 @default.
• W4220795434 hasBestOaLocation W42207954342 @default.
• W4220795434 hasConcept C126322002 @default.
• W4220795434 hasConcept C141071460 @default.
• W4220795434 hasConcept C164705383 @default.
• W4220795434 hasConcept C203092338 @default.
• W4220795434 hasConcept C207103383 @default.
• W4220795434 hasConcept C2778213512 @default.
• W4220795434 hasConcept C2778583881 @default.
• W4220795434 hasConcept C2779699572 @default.
• W4220795434 hasConcept C2780868729 @default.
• W4220795434 hasConcept C44249647 @default.
• W4220795434 hasConcept C500558357 @default.
• W4220795434 hasConcept C535046627 @default.
• W4220795434 hasConcept C71924100 @default.
• W4220795434 hasConceptScore W4220795434C126322002 @default.
• W4220795434 hasConceptScore W4220795434C141071460 @default.
• W4220795434 hasConceptScore W4220795434C164705383 @default.
• W4220795434 hasConceptScore W4220795434C203092338 @default.
• W4220795434 hasConceptScore W4220795434C207103383 @default.
• W4220795434 hasConceptScore W4220795434C2778213512 @default.
• W4220795434 hasConceptScore W4220795434C2778583881 @default.
• W4220795434 hasConceptScore W4220795434C2779699572 @default.
• W4220795434 hasConceptScore W4220795434C2780868729 @default.
• W4220795434 hasConceptScore W4220795434C44249647 @default.
• W4220795434 hasConceptScore W4220795434C500558357 @default.
• W4220795434 hasConceptScore W4220795434C535046627 @default.
• W4220795434 hasConceptScore W4220795434C71924100 @default.
• W4220795434 hasIssue "16" @default.
• W4220795434 hasLocation W42207954341 @default.
• W4220795434 hasLocation W42207954342 @default.

• next